AGC Biologics signs long-term manufacturing deal with global biopharma customer

PUBT · 2d ago
AGC Biologics signs long-term manufacturing deal with global biopharma customer
  • AGC Biologics, a unit of AGC, signed a long-term manufacturing agreement with a leading global biopharmaceutical company.
  • Deal covers development support, commercial manufacturing, global supply of multiple biopharmaceutical products.
  • AGC Biologics expects total revenue of several tens of billions of yen over the contract term.
  • Work will leverage AGC Biologics’ new Yokohama CDMO site, targeting GMP-compliant commercial services in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AGC Inc. published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.